Navigation Links
Randomized Study Comparing Cell Therapeutics' OPAXIO (Paclitaxel Poliglumex) and Radiotherapy to Standard of Care Temozolomide and Radiotherapy Treatment Open for Enrollment
Date:8/18/2011

leasing the paclitaxel chemotherapy.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.celltherapeutics.com/.

Sign up for email alerts and get RSS feeds at CTI's Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with OPAXIO in particular, including, without limitation, the potential failure of OPAXIO to prove safe and effective and/or less toxic and effective for the treatment of newly diagnosed high-grade malignant brain tumors such as GBM, including when combined with TMZ and RT, the potential failure of OPAXIO when combined with TMZ and RT to provide PFS and OS responses to newly-diagnosed high-grade malignant brain tumors such as GBM, that the results of the new OPAXIO study may not be positive or be used to plan a phase III study of OPAXIO for approval for use in treating newly diagnosed GBM, that CTI cannot predict or guarantee the pace of patient enrollment in the phase II clinical study comparing OPAXIO to TMZ, Brown  and CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling CTI's product candidates such as OPAXIO, and the risk factors listed or described from tim
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
2. Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone
3. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
4. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
5. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
6. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
7. Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans
8. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
9. Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial
10. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Sept. 22, 2014  WIRB-Copernicus Group (WCG), the ... services for clinical research, announced today that its ... been reaccredited by the Association for the Accreditation ... to improve safeguards for clinical research participants. ... Deieso , Ph.D., commented, "It is of utmost ...
(Date:9/22/2014)... Mass. , Sept. 22, 2014 ... GEVA ), a biopharmaceutical company developing therapeutic ... of Robert Bazemore as Chief Operating ... , President and Chief Executive Officer, Robert will ... company,s lead program, sebelipase alfa for LAL Deficiency, ...
(Date:9/21/2014)... to produce ultra-thin "diamond nanothreads" that promise extraordinary properties, ... strongest nanotubes and polymers. A paper describing this discovery ... a professor of chemistry at Penn State University, will ... the journal Nature Materials . , "From a ... the threads we formed have a structure that has ...
(Date:9/20/2014)... HealthTronics, Inc. , a leading ... and services, has signed a distribution agreement through ... for its high precision laser technology. ... mobile, surgical technology—offering more choices for healthcare providers ... will make available Clinicon’s FDA-cleared SureLase™ CO2 Laser ...
Breaking Biology Technology:Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Smallest possible diamonds form ultra-thin nanothreads 2Smallest possible diamonds form ultra-thin nanothreads 3Smallest possible diamonds form ultra-thin nanothreads 4HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3
... facility provides patients access to advanced gene-sequencing,technologies and ... SEATTLE, Oct. 16 Swedish Neuroscience,Institute (SNI) ... Center,s,newly renovated Cherry Hill Campus, the Center for ... its doors to patients diagnosed,with both benign and ...
... (AATI), based in Ames, IA will expand its office ... to current operations. The expansion,adjoins the current office space ... Park campus. Although the 35 person, 10 year old ... building on the,Research Park Campus, the expansion will make ...
... Promising Patient Solutions, MARQUETTE, Mich., Oct. ... in innovative medical devices, announced today the,successful ... spacer. The,nanOss(TM)- Cervical cage is machined from ... to function as bone.,The surgeries were performed ...
Cached Biology Technology:Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research 2Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research 3Swedish in Seattle Unveils State-of-the-Art Brain Tumor Center Combining Advanced Treatment With Innovation in Research 4Advanced Analytical Technologies, Inc. Expands Into New Office and Production Space 2Pioneer(R) Surgical Technology Announces First Human Implants of New nanOss(TM)-Cervical Fusion Device 2
(Date:9/21/2014)... main contributor to global warming, are set to rise again ... tonnes. , The 2.5 per cent projected rise in burning ... is co-led in the UK by researchers at the Tyndall ... Anglia and the College of Engineering, Mathematics and Physical Sciences ... the New York Climate Summit, where world leaders will seek ...
(Date:9/21/2014)... what was previously thought, newborn immune T cells may ... bacteria, according to a new study led by King,s ... to that of adults, babies may still be able ... published in the journal Nature Medicine . , ... types of immune cells, including neutrophils which play an ...
(Date:9/19/2014)... Call it the Jimmy Durante of dinosaurs ... nasal profile. The new dinosaur, named Rhinorex ... University and Brigham Young University, lived in what ... during the Late Cretaceous period. , Rhinorex, which ... and a close relative of other Cretaceous hadrosaurs ...
Breaking Biology News(10 mins):CO2 emissions set to reach new 40 billion ton record high in 2014 2CO2 emissions set to reach new 40 billion ton record high in 2014 3Immune system of newborn babies is stronger than previously thought 2New hadrosaur noses into spotlight 2
... World leaders have made pitiful progress on their guarantee to ... a paper published today (Friday 15th June) in Science ... researchers have reviewed commitments made by governments to protect the ... over the past 20 years. At the World ...
... found a surprising connection between a key DNA-repair process and ... and other chronic conditions. The discovery promises to open up ... could ultimately yield novel treatments for a wide variety of ... it goes against current dogma about the role of DNA ...
... the Instituto Andaluz de Ciencias de la Tierra and other ... published in the prestigious journal Reviews of Modern Physics ... different countries has published the most comprehensive study ever done ... important contemporary issues in a field of research that is ...
Cached Biology News:A sea of broken promises 2Scientists tie DNA repair to key cell signaling network 2Spanish scientist participate in the most comprehensive study ever done on ice 2
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Tube-O-DIALYZER Floats, small....
Nestin, Human...
Biology Products: